Stifel on Artivion Inc. (AORT): NEXUS FDA approval a clear positive
Tweet Send to a Friend
Stifel analyst John McAulay reiterated a Buy rating and $55.00 price target on Artivion Inc. (NYSE: AORT)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
